Vaccine · Immune activation, directed at neoantigens · developed by Nykode Therapeutics
Phase 1/2Most advanced trial (none active)
1Registered trials
What is VB10.NEO?
VB10.NEO is a vaccine supplied as a sterile, ready-to-use solution and given as a series of 14 vaccinations. It is studied in patients with locally advanced or metastatic solid tumours.
Summary written with AI from the sources listed at the end of this page.
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.